Application of orthobiological products in the treatment of osteoarthritis of knee joints
Year: 2022, volume 18 Issue: №3 Pages: 327-334
Heading: Traumatology and Orthopedics Article type: Original article
Authors: Gorbatenko A.I., Kostyanaya N.O., Malanin D.A., Sikilinda V.D., Demeshchenko M.V., Suchilin I.A., Kondrashenko V.V.
Organization: Volgograd State Medical University, Southern Federal University
Heading: Traumatology and Orthopedics Article type: Original article
Authors: Gorbatenko A.I., Kostyanaya N.O., Malanin D.A., Sikilinda V.D., Demeshchenko M.V., Suchilin I.A., Kondrashenko V.V.
Organization: Volgograd State Medical University, Southern Federal University
Summary:
Objective: to compare the effectiveness of treatment of patients with osteoarthritis stages II-III using orthobiological products, in particular autologous bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP), by intraosseous injection in the area of overload bone marrow edema. Material and methods. The prospective study conducted on the basis of two medical clinics from 2016 to 2019, involved 40 patients with knee OA of II-III using. The patients of the main (BMAC) group underwent a single intraosseous injection of BMAC, whereas the comparison (PRP) group undergoing a single intraosseous PRP injection. The results were assessed after 1, 3, 6, 12 months with VAS, Leken, WOMAC, and verbal rating scale (VRS). Results. After 12 months there was a decrease in the VAS index in the main group to 3.9±0.3 points, in the control group to 4.2±0.1 points, Leken in the main group 5.8±0.7 points, in the con- trol group to 6.1±0,8 points, WOMAC in the main group upto40.6±0.3 points, in the control group upto42.5±0.6 points. The assessment according to the VRS showed that in the control periods of 3 and 6 months. Patients' preferences were given in favor of treatment with autologous BMAC, while after 12 months the differences were not significant. Conclusion. Using orthobiological products for osteoarthritis treatment proved to be effective, with intraosseous BMAC injection proving more efficient compared to PRP injection in terms of pain, knee functionality, physical activity, and patients satisfaction during the entire observation period. Both methods of treatment proved to be safe.
Bibliography:
1. Alekseeva LI. Osteoarthritis: epidemiology, classification, risk factors and progression, clinic, diagnosis, treatment. Modern Rheumatology Journal 2019; 13 (2): 9-21.
2. Sanchez М, Anitua Е, Delgado D, et al. A new strategy to tackle severe knee osteoarthritis: Combination of intra-articular and intraosseous injections of Platelet Rich Plasma. Expert Opinion on Biological Therapy 2016; (10): 15-7.
3. Shapiro SA, Kazmerchak SE, Heckman MG, et al. Prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis randomized controlled trial. Am J Sports Med 2017; 45 (1): 82-90.
4. Sharkey PF, Cohen SB, Leinberry ChF, Parvizi J. Sub-chondral bone marrow lesions associated with knee osteoarthritis. Am J Orthop 2012; 41 (9): 413-7.
5. Su K, Bai Y, Wang J, et al. Comparison of hyaluronicacid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. 2018; (37): 1341-50.
6. Malanin DA, Demeshhenko MV, Cherezov LL, Gru-nin SV. The efficacy of platelet-rich plasma in the treatment of patients with osteoarthritis of the knee. Practical Medicine. 2020;
18 (4): 29-35.
7. Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 2013; (41): 356-64.
8. Lychagin AV, Garkavi AV, Islejih Ol, et al. Efficiency of intraosseous injection of autologous platelet-rich plasma into the area of bone marrow edema in osteoarthritis of the knee joint. Bulletin of Russian State Medical University 2019; (4): 50-6.
9. Kobayashi Y, Saita Y, Nishio H, et al. leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci 2016; 21 (5): 683-9.
10. Kon E, Di Matteo B, Delgado D, etal. Platelet-rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding system. Expert Opin Biol Ther 2020; 20 (12): 1447-60.
| Attachment | Size |
|---|---|
| 2022_3_327-334.pdf | 799.33 KB |
Русский
English